GrowthFormulaNCT01158352
Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children
A study testing Nutritional supplementation formula in people with Growth and Low Weight, run by Rabin Medical Center at 1 site in Israel.
Trial summary
Study design: Double blind, randomized, placebo controlled study.The proposed study will consist of two main segments: 1. Segment 1 is aimed to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean prepubertal children on weight SDS, height SDS, BMI SDS and… Read more about this study
- Who is it for?
- Ages 3 to 8 years
- Conditions the study is for
- Growth, Low Weight, Low Height
- What is being tested?
- Nutritional supplementation formula
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 1 siteIsrael
- Study dates
- Nov 2010to Nov 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 8 years
- All sexes
- No healthy volunteers
- Child
Inclusion Criteria for participants at the intervention group (segments 1\&2):
- Girls aged 3-7 years old and boys aged 3-8 years old
- Prepubertal - tanner stage 1
- Height, weight and BMI < 10th percentile for age and gender
- Availability of growth velocity data for at least 4 months prior to study entry.
- Signing inform consent forms
Exclusion Criteria for participants at the intervention group (segments 1):
- Diagnosis of GH Deficiency or treatment with GH
- Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems
- Any known gastrointestinal problem including absorption problems
- Any known organic reason for slow growth
- Any chronic treatment with medication that might effects appetite (for example SSRI's), weight or Growth.
Inclusion Criteria for participants at the control group (segments 2):
- Girls aged 3-8 years old and boys aged 3-9 years old
- Prepubertal - tanner stage 1
- Height ≥ 25th percentile for age and gender
- Proper proportion between weight and height- 5th ≤ BMI ≤ 85th
- Signing inform consent forms
Exclusion Criteria for participants at the control group (segments 2):
- Diagnosis of GH Deficiency or treatment with GH
- Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems
- Any known gastrointestinal problem including absorption problems
- Any known organic reason for slow growth
- Any chronic treatment with medication that might effects appetite (for example SSRI's), weight or Growth
- Children with growth faltering during the previous year
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children
Study design:
Double blind, randomized, placebo controlled study.The proposed study will consist of two main segments:
Read more
- Segment 1 is aimed to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean prepubertal children on weight SDS, height SDS, BMI SDS and growth velocity
- Segment 2 is aimed to explore the eating behavior of idiopathic short stature and lean prepubertal children against their sibling who have a normal height and body weight and to find out whether there is a difference in eating patterns and quality of life between idiopathic short stature and lean prepubertal children and children with normal height and body weight
Segment 1
Population:
200 subjects and controls will be recruited to segment 1 of the proposed study, 100 at each group.
Participants will be recruited from healthy children who will be referred to either the institute for endocrinology or the gastroenterology unit, at Schneider Children's Medical Center for growth assessment, due to low height and weight, in whom, no gastrointestinal morbidity or other underlying cause was found.
Methods:
Randomization \& Blinding:
Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the first 6 months of the study.
Treatment:
Participants in the intervention group will be treated with a nutritional supplementation standardized formula.Participants in the control group will be instructed to consume the same volume of formula as was calculated if they were in the intervention group.
Treatment duration:
The study will be divided into two treatment periods: 6 months of intervention versus active placebo followed with additional 6 months (an extension period), in which participants at the intervention group will be offered to extend the intervention period and participants at the control arm will be offered to switch to the intervention group.
Study Schedule:
Follow up visits will take place at 0, 3, 6, 9 and 12 months and will include:
- Demographic data, medical history and growth data (month 0): Demographic parameters, including birth date, gender, birth weight and length for gestational age, medical history and growth data, including height velocity, parent's and sibling's weight and height will be documented from patient's file.
- Nutritional assessment
- Anthropometric assessment (months 0, 3, 6, 9 12):
- Height without shoes
- Length
- Weight with light cloths and without shoes
- MAC
- Body mass index (BMI) will be calculated from children's weight and height and age and gender specific BMI SDS will be calculated
- Body composition assessment using the method of bioelectrical impedance
- Laboratory parameters (months 0, 6 and 12):
- Sleeping Questionaire
Segment 2:
86 subjects and controls will be recruited to segment 2 of the proposed study
Population:
Short and lean prepubertal children participating at segment 1 of the study and who are at study entry under 10th percentile in height, when the weight percentile is equal or smaller to the height percentile. Only participants from segment 1 who have siblings with normal height and body weight for age and gender, will be able to participate in segment 2 of the study
Control group 1:
Sibling of participants in segment 1 of the study, who have a normal height- above 25th percentile and normal BMI for age and gender- above 5th percentile and under 85th percentile.
Control group 2:
Healthy children from the community who have a normal height above 25th percentile and normal BMI for age and gender above 5th percentile and under 85th percentile
Segment 2 of the study will be designed as a case- control study and will focus on the eating patterns, sleeping patterns and quality of life of participants at segment 1 at time 0 month of the study, before the beginning of the nutrition intervention. These findings will be compared to data of a control group, which will be comprised of siblings of participants in segment 1, with normal height and body weight which are matched in age.
- Conditions
- Growth, Low Weight, Low Height
- Being tested
- Nutritional supplementation formula, Placebo Comparator
- Keywords
- Growth, Low weight, Low height, Nutritional Formula
- Medical subject headings
- Thinness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nutritional supplementation formulaDietary supplement
Nutritional supplementation formula
Placebo ComparatorDietary supplement
Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
| Study group | Role | What they receive |
|---|---|---|
| Nutritional supplemntation formula | Experimental | Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake) Receives: Dietary Supplement: Nutritional supplementation formula |
| Placebo Comparator | Placebo comparator | Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals Receives: Dietary Supplement: Placebo Comparator |
What is being measured
The primary outcome is the main question the study is designed to answer.
Height SDS (standard deviation score)
standard deviation score of patient's height at 12 months
Measured: At 12 months
Secondary outcomes (8)
Weight SDS (standard deviation score)
Standard deviation score of patient's weight at 12 months
Measured: At 12 months
Weight/Height SDS (standard deviation score)
Standard deviation score of patient's Weight / Height ratio at 12 months
Measured: At 12 months
BMI SDS (standard deviation score)
standard deviation score of patient's BMI at 12 months
Measured: At 12 months
Growth Velocity
Measured: At 12 months
5.Sleeping Questionaire
Measured: At 12 months
Child Eating Behaviour Questionaire (CEBQ)
Measured: At 12 months
3-day food diary
Measured: At 12 months
Physical activity questionnaire
Measured: At study entry
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2010 (estimated)
- Study startNov 2010
- Primary completionNov 2014
- Study completionNov 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for GrowthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rabin Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Moshe Phillip, Prof, Principal investigator, Schenider Children's Medical
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01158352
- Sponsor's protocol ID
- rmc005547ctil
- Acronym
- Formula
- Status last verified
- Nov 2014
- First submitted
- 27 Jun 2010
- Last updated
- 7 Nov 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Yackobovitch-Gavan M, Lebenthal Y, Lazar L, Shalitin S, Demol S, Tenenbaum A, Shamir R, Phillip M. Effect of Nutritional Supplementation on Growth in Short and Lean Prepubertal Children after 1 Year of Intervention. J Pediatr. 2016 Dec;179:154-159.e1. doi: 10.1016/j.jpeds.2016.08.100. Epub 2016 Sep 30.
PubMed 27697330Lebenthal Y, Yackobovitch-Gavan M, Lazar L, Shalitin S, Tenenbaum A, Shamir R, Phillip M. Effect of a nutritional supplement on growth in short and lean prepubertal children: a prospective, randomized, double-blind, placebo-controlled study. J Pediatr. 2014 Dec;165(6):1190-1193.e1. doi: 10.1016/j.jpeds.2014.08.011. Epub 2014 Sep 17.
PubMed 25241181
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children
- ClinicalTrials.gov ID
- NCT01158352
- Acronym / sponsor ID
- Formula / rmc005547ctil
- Conditions
- Growth, Low Weight, Low Height
- Keywords
- Growth, Low weight, Low height, Nutritional Formula
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Rabin Medical CenterUniversity, hospital or other
- Study start
- Nov 2010
- Primary completion
- Nov 2014 (actual)
- Study completion
- Nov 2014 (actual)
- First posted
- 8 Jul 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study design:
Double blind, randomized, placebo controlled study.The proposed study will consist of two main segments:
- Segment 1 is aimed to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean prepubertal children on weight SDS, height SDS, BMI SDS and growth velocity
- Segment 2 is aimed to explore the eating behavior of idiopathic short stature and lean prepubertal children against their sibling who have a normal height and body weight and to find out whether there is a difference in eating patterns and quality of life between idiopathic short stature and lean prepubertal children and children with normal height and body weight
Segment 1
Population:
200 subjects and controls will be recruited to segment 1 of the proposed study, 100 at each group.
Participants will be recruited from healthy children who will be referred to either the institute for endocrinology or the gastroenterology unit, at Schneider Children's Medical Center for growth assessment, due to low height and weight, in whom, no gastrointestinal morbidity or other underlying cause was found.
Methods:
Randomization \& Blinding:
Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the first 6 months of the study.
Treatment:
Participants in the intervention group will be treated with a nutritional supplementation standardized formula.Participants in the control group will be instructed to consume the same volume of formula as was calculated if they were in the intervention group.
Treatment duration:
The study will be divided into two treatment periods: 6 months of intervention versus active placebo followed with additional 6 months (an extension period), in which participants at the intervention group will be offered to extend the intervention period and participants at the control arm will be offered to switch to the intervention group.
Study Schedule:
Follow up visits will take place at 0, 3, 6, 9 and 12 months and will include:
- Demographic data, medical history and growth data (month 0): Demographic parameters, including birth date, gender, birth weight and length for gestational age, medical history and growth data, including height velocity, parent's and sibling's weight and height will be documented from patient's file.
- Nutritional assessment
- Anthropometric assessment (months 0, 3, 6, 9 12):
- Height without shoes
- Length
- Weight with light cloths and without shoes
- MAC
- Body mass index (BMI) will be calculated from children's weight and height and age and gender specific BMI SDS will be calculated
- Body composition assessment using the method of bioelectrical impedance
- Laboratory parameters (months 0, 6 and 12):
- Sleeping Questionaire
Segment 2:
86 subjects and controls will be recruited to segment 2 of the proposed study
Population:
Short and lean prepubertal children participating at segment 1 of the study and who are at study entry under 10th percentile in height, when the weight percentile is equal or smaller to the height percentile. Only participants from segment 1 who have siblings with normal height and body weight for age and gender, will be able to participate in segment 2 of the study
Control group 1:
Sibling of participants in segment 1 of the study, who have a normal height- above 25th percentile and normal BMI for age and gender- above 5th percentile and under 85th percentile.
Control group 2:
Healthy children from the community who have a normal height above 25th percentile and normal BMI for age and gender above 5th percentile and under 85th percentile
Segment 2 of the study will be designed as a case- control study and will focus on the eating patterns, sleeping patterns and quality of life of participants at segment 1 at time 0 month of the study, before the beginning of the nutrition intervention. These findings will be compared to data of a control group, which will be comprised of siblings of participants in segment 1, with normal height and body weight which are matched in age.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nutritional supplemntation formula | Experimental | Dietary Supplement: Nutritional supplementation formulaNutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake) |
| Placebo Comparator | Placebo comparator | Dietary Supplement: Placebo ComparatorPlacebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals |
Who may qualify
- Ages
- 3 to 8 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nutritional supplementation formulaNutritional supplementation formula | Dietary supplement | Nutritional supplemntation formula |
| Placebo ComparatorPlacebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals | Dietary supplement | Placebo Comparator |
Primary outcome
Height SDS (standard deviation score)
Time frame: At 12 months
standard deviation score of patient's height at 12 months
8 secondary outcomes
Weight SDS (standard deviation score)
Time frame: At 12 months
Weight/Height SDS (standard deviation score)
Time frame: At 12 months
BMI SDS (standard deviation score)
Time frame: At 12 months
Growth Velocity
Time frame: At 12 months
5.Sleeping Questionaire
Time frame: At 12 months
Child Eating Behaviour Questionaire (CEBQ)
Time frame: At 12 months
3-day food diary
Time frame: At 12 months
Physical activity questionnaire
Time frame: At study entry
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2014.
- Derived from this study: PubMed 27697330Yackobovitch-Gavan M, Lebenthal Y, Lazar L, Shalitin S, Demol S, Tenenbaum A, Shamir R, Phillip M. Effect of Nutritional Supplementation on Growth in Short and Lean Prepubertal Children after 1 Year of Intervention. J Pediatr. 2016 Dec;179:154-159.e1. doi: 10.1016/j.jpeds.2016.08.100. Epub 2016 Sep 30.
- Derived from this study: PubMed 25241181Lebenthal Y, Yackobovitch-Gavan M, Lazar L, Shalitin S, Tenenbaum A, Shamir R, Phillip M. Effect of a nutritional supplement on growth in short and lean prepubertal children: a prospective, randomized, double-blind, placebo-controlled study. J Pediatr. 2014 Dec;165(6):1190-1193.e1. doi: 10.1016/j.jpeds.2014.08.011. Epub 2014 Sep 17.
Related trials for Growth
Recruiting
Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy
Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer
RecruitingPhase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
RecruitingPhase 1/2
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
EGFR-Mutant Non-Small Cell Lung Cancer
Active, not recruitingPhase 2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Moshe Phillip, Prof principal investigator
Schenider Children's Medical
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nutritional supplementation formula in people with Growth and Low Weight, run by Rabin Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Nov 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Height SDS (standard deviation score) (time frame: At 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01158352, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2014.